NCLEX Review Guide: Liver Cirrhosis

Definition & Process

• Liver cirrhosis is a chronic, progressive liver disease characterized by diffuse hepatic fibrosis and the conversion of normal liver architecture into structurally abnormal nodules. This irreversible condition results from sustained liver injury that leads to scarring and eventual loss of liver function.
• The pathological process involves hepatocyte necrosis followed by fibrosis and regenerative nodule formation, which disrupts normal blood flow through the liver and impairs hepatic function.

Etiology

• Alcoholic liver disease: Chronic alcohol consumption is the leading cause of cirrhosis in Western countries, with risk increasing proportionally to the amount and duration of alcohol intake.
• Viral hepatitis: Chronic hepatitis B and C infections can progress to cirrhosis over decades if left untreated.
• Nonalcoholic fatty liver disease (NAFLD): Increasingly common cause, associated with obesity, diabetes, and metabolic syndrome.
• Other causes include autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis, hemochromatosis, Wilson's disease, alpha-1 antitrypsin deficiency, and drug-induced liver injury.

Early Signs & Symptoms

• Early cirrhosis is often asymptomatic (compensated phase) with patients experiencing nonspecific symptoms such as fatigue, weakness, anorexia, weight loss, and vague right upper quadrant abdominal discomfort.
• Laboratory abnormalities may be the first indication of liver disease, including elevated liver enzymes (AST, ALT), decreased albumin, and prolonged prothrombin time.

Portal Hypertension Manifestations

• Ascites: Accumulation of fluid in the peritoneal cavity due to increased hydrostatic pressure in portal circulation and decreased albumin production by the damaged liver.
• Esophageal varices: Dilated veins in the esophagus that develop as blood seeks alternate routes around the obstructed liver; these can rupture and cause life-threatening hemorrhage.
• Splenomegaly: Enlargement of the spleen due to congestion from portal hypertension, often leading to thrombocytopenia from increased platelet sequestration.
• Caput medusae: Dilated periumbilical veins that radiate from the umbilicus, representing collateral circulation between portal and systemic venous systems.

Hepatic Encephalopathy

• Hepatic encephalopathy is a neuropsychiatric syndrome characterized by altered mental status, ranging from subtle cognitive deficits to coma, resulting from the liver's inability to clear neurotoxins (primarily ammonia) from the bloodstream.
• Clinical manifestations progress through stages: Stage 1 (mild confusion, personality changes), Stage 2 (lethargy, disorientation), Stage 3 (somnolence, marked confusion), and Stage 4 (coma).
• Characteristic findings include asterixis (flapping tremor), hyperreflexia, and fetor hepaticus (musty breath odor).

Other Manifestations

• Jaundice: Yellowing of skin and sclera due to hyperbilirubinemia, indicating significant hepatocellular dysfunction.
• Coagulopathy: Decreased production of clotting factors leading to easy bruising, bleeding gums, and prolonged bleeding times.
• Hepatorenal syndrome: Progressive renal failure in patients with advanced liver disease, characterized by reduced renal perfusion without structural kidney damage.
• Hepatopulmonary syndrome: Hypoxemia due to intrapulmonary vascular dilatations causing ventilation-perfusion mismatch.
• Endocrine changes: Gynecomastia, testicular atrophy, and menstrual irregularities due to altered metabolism of sex hormones.
• Skin changes: Spider angiomas, palmar erythema, Terry's nails (white nails with distal pink band), and Dupuytren's contracture.

Laboratory Tests

• Liver function tests: AST and ALT elevations (may normalize in advanced cirrhosis), elevated alkaline phosphatase and GGT, prolonged PT/INR, decreased albumin, and elevated bilirubin.
• Complete blood count: May show thrombocytopenia (due to splenomegaly), anemia (from GI bleeding or nutritional deficiencies), and leukopenia or leukocytosis.
• Serum electrolytes: May reveal hyponatremia (dilutional from fluid retention or true hyponatremia from impaired free water clearance).
• Etiologic testing: Hepatitis viral serologies, autoimmune markers, iron studies, ceruloplasmin (Wilson's disease), alpha-1 antitrypsin levels, and drug/toxin screens.

Imaging Studies

• Ultrasound: First-line imaging modality that can show nodular liver surface, increased echogenicity, splenomegaly, and signs of portal hypertension; Doppler studies assess portal vein flow and patency.
• CT scan: Provides detailed images of liver morphology, nodularity, and can detect complications such as HCC or portal vein thrombosis.
• MRI/MR elastography: Superior for characterizing focal lesions and assessing liver stiffness (fibrosis).
• Transient elastography (FibroScan): Non-invasive method to assess liver stiffness and estimate the degree of fibrosis.

Liver Biopsy

• Considered the gold standard for definitive diagnosis of cirrhosis, liver biopsy provides histological confirmation of fibrosis, nodule formation, and can help identify the underlying etiology.
• Approaches include percutaneous, transjugular, laparoscopic, or image-guided techniques, with the method selected based on patient factors and contraindications.

Endoscopic Evaluation

• Upper endoscopy is essential for screening and grading esophageal and gastric varices, allowing for risk stratification and prophylactic intervention.
• All patients with newly diagnosed cirrhosis should undergo endoscopic screening for varices, with follow-up intervals determined by findings and clinical status.

Assessment

• Perform comprehensive assessment focusing on signs of hepatic decompensation: mental status changes, jaundice, ascites, peripheral edema, and bleeding tendencies.
• Monitor vital signs with attention to hypotension (indicating possible GI bleeding or infection) and tachycardia (may suggest hypovolemia or infection).
• Assess abdominal circumference and daily weight to track ascites progression or response to diuretic therapy.
• Perform detailed neurological assessment using tools like the West Haven Criteria or Glasgow Coma Scale to detect and grade hepatic encephalopathy.

Management of Ascites

• Implement sodium restriction (2000 mg/day or less) and fluid restriction if hyponatremia is present (serum sodium <130 mEq/L).
• Administer diuretic therapy as prescribed, typically starting with spironolactone (aldosterone antagonist) and adding furosemide as needed. Monitor for electrolyte imbalances, especially hypokalemia and hyponatremia.
• Prepare patients for paracentesis (therapeutic removal of ascitic fluid) when indicated, and monitor for complications such as hypotension, infection, or bleeding.
• For large-volume paracentesis (>5 liters), administer albumin replacement (6-8 g/L of fluid removed) to prevent post-paracentesis circulatory dysfunction.

Management of Hepatic Encephalopathy

• Administer lactulose as prescribed to reduce ammonia production and absorption in the intestine. Titrate to achieve 2-3 soft bowel movements daily.
• Administer rifaximin (non-absorbable antibiotic) as prescribed to reduce ammonia-producing bacteria in the gut.
• Identify and address precipitating factors: GI bleeding, infection, constipation, electrolyte imbalances, or medication non-compliance.
• Implement safety measures for confused patients, including fall prevention, reorientation strategies, and potentially 1:1 observation for severe encephalopathy.

1. Assess mental status using standardized tools (West Haven Criteria).
2. Check for asterixis by having the patient extend arms with wrists dorsiflexed.
3. Administer lactulose per protocol, typically starting with 25-30 mL orally every 1-2 hours until bowel movement occurs.
4. Maintain bowel movement record to guide lactulose dosing adjustments.
5. Monitor for dehydration and electrolyte imbalances from excessive diarrhea.
6. Reassess mental status regularly to evaluate treatment effectiveness.

Management of Variceal Bleeding

• Variceal hemorrhage is a life-threatening emergency requiring immediate intervention. Mortality rates approach 20% per bleeding episode.
• Establish large-bore IV access (two sites minimum) and initiate fluid resuscitation while avoiding overresuscitation, which can increase portal pressure.
• Prepare for blood product administration as ordered (packed red blood cells, fresh frozen plasma, platelets) with target hemoglobin of 7-8 g/dL.
• Administer vasoactive medications as prescribed (octreotide, terlipressin, or somatostatin) to reduce portal pressure.
• Prepare patient for endoscopic therapy (band ligation or sclerotherapy) and assist with coordination of emergency endoscopy.
• Administer prophylactic antibiotics as prescribed to prevent infection, which is common after variceal bleeding.

Nutritional Support

• Provide adequate caloric intake (35-40 kcal/kg/day) and protein (1.2-1.5 g/kg/day) to prevent muscle wasting and improve nutritional status.
• Administer vitamin supplementation as prescribed, particularly fat-soluble vitamins (A, D, E, K) and B vitamins, which are commonly deficient in cirrhotic patients.
• Consider branched-chain amino acid supplements for patients who remain encephalopathic despite standard therapy.
• Provide small, frequent meals to improve intake and prevent prolonged fasting, which can worsen hepatic encephalopathy.

Medication Management

• Use caution with all medications as cirrhosis affects drug metabolism and clearance. Many medications require dose adjustment or may be contraindicated.
• Avoid hepatotoxic medications, including acetaminophen (>2 g/day), NSAIDs, and certain antibiotics. Consult with pharmacy for medication safety review.
• Monitor for adverse effects of beta-blockers used for variceal prophylaxis, including hypotension, bradycardia, and worsening ascites.
• Administer prophylactic antibiotics as prescribed for high-risk patients (e.g., norfloxacin or ciprofloxacin for SBP prevention in patients with prior SBP or low ascitic protein).

Patient Education

• Educate patients about complete abstinence from alcohol, regardless of the underlying cause of cirrhosis.
• Provide detailed instructions on sodium restriction, medication regimens, and recognition of warning signs requiring medical attention.
• Teach patients and caregivers about hepatic encephalopathy signs and the importance of adherence to lactulose therapy.
• Discuss the importance of regular medical follow-up, including surveillance for hepatocellular carcinoma and variceal screening.
• Provide information about liver transplantation when appropriate, including evaluation process and candidacy requirements.

• Cirrhosis is an irreversible, chronic liver disease characterized by fibrosis and nodule formation, resulting from various etiologies including alcohol, viral hepatitis, and NAFLD.
• Major complications include portal hypertension (leading to ascites, varices, and splenomegaly), hepatic encephalopathy, coagulopathy, and increased risk for hepatocellular carcinoma.
• Diagnostic assessment includes laboratory tests (liver function tests, coagulation studies), imaging (ultrasound, CT, MRI), and sometimes liver biopsy.
• Nursing management focuses on monitoring for complications, managing ascites and encephalopathy, preventing variceal bleeding, providing nutritional support, and patient education.
• Prevention of further liver damage through alcohol abstinence, hepatitis treatment, and metabolic control is essential regardless of the original cause.

NCLEX Question Strategies

• For questions about hepatic encephalopathy, remember that identifying and treating precipitating factors is a priority nursing intervention.
• When answering questions about variceal bleeding, prioritize actions that focus on hemodynamic stabilization and reducing portal pressure.
• For medication questions, remember that patients with cirrhosis require careful medication selection and often dose adjustments due to altered drug metabolism.
• In questions about ascites management, look for answers that include both sodium restriction and diuretic therapy as first-line interventions.